PolarityTE: Up on forming strategic review committee to raise shareholder value

RegenETP,

11/01/2021 13:47

** Shares of regenerative tissue developer  PTE.O  jump 15%
to $1.52 premarket 
    ** Co says board has formed strategic review committee to
enhance shareholder value; to review operational strategies that
advance regulatory process for SkinTE and future financing
    ** SkinTE is human cellular and tissue-based product derived
from patient's own skin to regenerate skin with all its layers
    ** "The Board believes that, working with the FDA, the
pursuit of a biologics license application for SkinTE is the
right path to improving shareholder value in the future" - Board
Chairman Peter Cohen  urn:newsml:reuters.com:*:nBw92JlfPa
    ** Cohen says co's lead asset SkinTE offers tremendous
benefits to patients suffering from debilitating wounds
    ** Committee also to review potential strategic
opportunities and make recommendations to the board 

 (Reporting by Sanjana Shivdas in Bengaluru)
 ((SanjanaSitara.Shivdas@thomsonreuters.com; within U.S. +1 646
223 8780, outside U.S. +91 80 6749 1642; Twitter:
@SanjanaShivdas;))